Please enable JavaScript.
Coggle requires JavaScript to display documents.
POSITIONING THE NONAVALENT HPV VACCINE, 8148258_orig - Coggle Diagram
POSITIONING THE NONAVALENT HPV VACCINE
PRICE
MORE EXPENSIVE THAN THE COMPETITION
STATE AND OUT-OF-POCKET WTP
STAKEHOLDERS WANT TO KNOW WHAT MAKES IT WORTH IT
Broader coverage means longer protection--future proofing
RESPONSE TO COST-EFFECTIVENESS ANALYSIS
CHANGE OF PERSPECTIVE FROM EFFECTIVE --> EFFICIENT
ETHICAL CONSIDERATIONS
PRAGMATISM VS BENEFICENCE
CLINICIANS: BENEFICENCE
AS MUCH AS POSSIBLE, NOT TREATING PEOPLE AS A MEANS TO AN END
PUBLIC HEALTH AND GOVERNMENT: PRAGMATISM
AT THE CURRENT STATE, THEY CANNOT AFFORD TO BE KANTIAN
PLACE
NEED FOR FOLLOW-UP
LOW FOLLOW-UP RATES FOR VACCINATION
RESOURCES NEEDED FOR FOLLOWING UP PUBLIC
ACCESS
FULLY GOVERNMENT SUBSIDIZED OR HALF-HALF
MOTHER'S HEALTH ILLITERACY
INFORMATION COMES FROM THE CHILD
GENERAL PUBLIC'S HEALTH ILLITERACY
CONSIDERABLE VACCINE ANXIETY/HESITANCY
PRODUCT
EFFECTIVE BASED ON HIGH-LEVEL EVIDENCE
ESPECIALLY DOUBLE-DOSE VACCINATION
WHO VS LOCAL GUIDELINES (PENDING UPDATES)
CONCERNS REGARDING SUPPLY SUSTAINABILITY
IDEAL
EXPANSIVE
NO UPDATED SEROTYPING DATA AVAILABLE YET IN THE COUNTRY
LASTS A LIFETIME
"IF IT WAS JUST FOR ME, I'D CHOOSE IT; BUT, AS A PH PRACTITIONER, IT'S NOT PRACTICAL"
"GOOD ENOUGH" VS "CAN'T PASS UP"
PROMOTION
INFORMATION REGARDING BOTH DISEASE AND VACCINE
CONSIDER REFRAMING INSTEAD AS CANCER PREVENTION, RATHER THAN INFECTION PREVENTION
UTILIZE INFORMAL COMMUNITY CIRCLES
IMPORTANCE OF DIGITAL ADVERTISING
